中國醫藥(600056.SH):子公司的注射用阿昔洛韋通過一致性評價
格隆匯6月1日丨中國醫藥(600056.SH)公吿,近日,公司下屬子公司湖北科益藥業股份有限公司(“科益藥業”)獲得國家藥品監督管理局核准簽發的注射用阿昔洛韋(“該藥品”)《藥品補充申請批准通知書》,該藥品通過仿製藥質量和療效一致性評價。
阿昔洛韋是用於治療皰疹的抗病毒藥。用於單純皰疹病毒感染、帶狀皰疹及免疫缺陷者水痘的治療。截至公吿披露日,國內生產廠家廣州一品紅製藥有限公司已通過該藥品的一致性評價,公司為國內第2家通過該藥品一致性評價的企業。
根據國家相關政策,通過一致性評價的藥品品種在醫保支付及醫療機構採購等領域將獲得更大的支持力度。科益藥業的注射用阿昔洛韋通過仿製藥質量和療效一致性評價,有利於擴大該藥品的市場份額。同時,為公司後續開展一致性評價工作積累寶貴的經驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.